Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA.
Stem Cells Transl Med. 2013 Feb;2(2):136-42. doi: 10.5966/sctm.2012-0125. Epub 2013 Jan 24.
Clinical organ transplantation became possible only after powerful immunosuppressive drugs became available to suppress the alloimmune response. After decades of solid organ transplantation, organ rejection is still a major challenge. However, significant insight into allorecognition has emerged from this vast experience and should be used to inform future stem cell-based therapies. For this reason, we review the current understanding of selected topics in transplant immunology that have not been prominent in the stem cell literature, including immune responses to ischemia/reperfusion injuries, natural killer cells, the adaptive immune response, some unresolved issues in T-cell allorecognition, costimulatory molecules, and the anticipated role of regulatory T cells in graft tolerance.
临床器官移植只有在具有强大免疫抑制作用的药物问世后才能成为可能,这些药物可抑制同种免疫反应。经过几十年的实体器官移植,器官排斥仍然是一个主要挑战。然而,从这一巨大的经验中涌现出了对同种异体识别的重要认识,这些认识应该用于指导未来基于干细胞的治疗。基于此,我们综述了移植免疫学中当前对一些未在干细胞文献中突出的选定主题的理解,包括对缺血/再灌注损伤、自然杀伤细胞、适应性免疫反应、T 细胞同种异体识别中一些未解决的问题、共刺激分子的免疫反应,以及调节性 T 细胞在移植物耐受中的预期作用。